BIOSGN — Biosergen AB Income Statement
0.000.00%
Last trade - 00:00
- SEK17.28m
- SEK15.40m
2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | PRESS | PRESS |
Standards: | SAS | SAS | — | — |
Status: | Final | Final | Final | Final |
Revenue | ||||
Total Revenue | 0 | 0 | — | — |
Cost of Revenue | ||||
Gross Profit | 0 | -0.178 | — | — |
Selling / General / Administrative Expenses | ||||
Other Operating Expenses | ||||
Total Operating Expenses | 6.23 | 34.1 | 40 | 27.3 |
Operating Profit | -6.23 | -34.1 | -40 | -27.3 |
Total Net Non Operating Interest Income / Expense | ||||
Net Income Before Taxes | -6.72 | -34.3 | -39.9 | -27 |
Provision for Income Taxes | ||||
Net Income After Taxes | -6.72 | -34.3 | -39.9 | -27 |
Net Income Before Extraordinary Items | ||||
Net Income | -6.72 | -34.3 | -39.9 | -27 |
Income Available to Common Shareholders Excluding Extraordinary Items | ||||
Income Available to Common Shareholders Including Extraordinary Items | ||||
Diluted Net Income | -6.72 | -34.3 | -39.9 | -27 |
Diluted Weighted Average Shares | ||||
Basic EPS Including Extraordinary Items | ||||
Diluted EPS Including Extraordinary Items | ||||
Diluted EPS Excluding Extraordinary Items | ||||
Normalised Income Before Taxes | ||||
Normalised Income After Taxes | ||||
Normalised Income Available to Common Shareholders | ||||
Diluted Normalised EPS | -0.126 | -0.642 | -0.757 | -0.313 |
Dividends per Share |